Flashcards in Overactive immune and immune suppressants Deck (31):
Small soluble proteins, normally innocuous, to which the mounts an immune defense.
Type 1 hypersensitivity
Mediated by IgE. Trend towards Th2 response.
Mast Cells and IgE
Mast cells bind to the Fc region of antibodies. Mast cell discharges granulates containing cytotoxic and inflammatory mediators (histamine, TNF, . Histamine, causes expansion of blood vessels, bronchii restriction.
Allergy activation: 3 stages
-B cell processes antigen
-T cells activate (Th2)
-IgE binds FcR on mast cells
-Occurs within minutes of exposure.
-Allergen recognized by IgE on mast cells.
-Mast cells release granulates.
-Release histamine, prostaglandin.
-recruit inflammatory cells. Eosinophils.
Type of T cells and in regards to allergies.
T helper cells release cytokines that mediate the immune response. However, during proliferation, T cells become many different types, each of which produces different cytokines (ILs), thereby mediating a different response. Allergic response depends greatly on the type of T helper cells.
Antibody dependent: types 1,2,3. Evident within hours. Quick response.
-Type 1: IgE -asthma, allergies,
-Type 2: IgG -drug allergies
-Type 3: IgG
Type 4 is T cell mediated. Delayed sensitivity, requires at least a day to develop.
Fc Receptors and IgG/IgE
Antibody based hypersensitivity involves the binding of an immune cell to the FC region of an antibody.
Type 1 hypersensivity is the result if IgE binding to immune cells. Granulocytes (mast cells, basophils, and eosinophils) have FcRs that bind to IgE.
Type 2 and 3 are the result of IgG binding to immune cells. FcRs that bind to IgG are expressed on macrophages, neutrophils, natural killer cells, and dendritic cells.
Type 2 hypersensitivity
Antibody dependent. IgG. Recruits macrophages and natural killer cells.
Generally drug allergies. Eg. penicillin.
Type 3 hypersensitivity
Antibody dependent. IgG. Recruits inflammatory cells and complement activation, driving granulate release.
Deposition in joints. Arthritis. Fibrosis.
Type 4 hypersensitivity
T cell driven. Take longer to mount.
Contact dermatitis. Antigen usually bind with proteins on epithelial cells. T Cells cells against allergen will kill skin cells. Release of cytokines promotes inflammation.
When tolerance to self goes wrong. A complex range of disorders. They can be organ specific or systemic.
Organ specific: Type 1 diabetes, Multiple sclerosis, Myasthenia gravia.
Systemic: Rheumatoid arthritis, lupus.
B and T cells that recognize self are killed, both during their development and while in the periphery.
-occurs in primary lymphoid organs
-bone marrow, thymus
-Cells that react to self are killed by negative selection.
-some auto reactive T/B cells escape detection are either the peripheral system.
-They are suppressed by T regulatory cells, which secrete immunosuppressive cytokines (IL 10, TGF).
T regulatory cells
They are a type of T cell that act to suppress activation of immune system, preventing activation in response to self-antigens. they work by secreting immunosuppressive cytokines (IL 10, TGF).
How does autoimmunity develop?
Genetic predisposition in genes that activate or turn off immune system.
Types of autoimmunities (2)
-Cell mediated immunity (T cell activation)
Antibody driven autoimmunity (autoantibodies)
Can change function by blocking interactions.
Or can drive type 2/3 hypersensitivities.
-Lupus, type 3 systemic.
Antibodies against nAChRs at NMJ block their function.
Systemic Lupus Erythematous
SLS is a chronic, multi organ disease affecting mainly women.
Characterized by the production of antibodies against DNA/RNA binding proteins (anti-nuclear proteins).
T Cell driven autoimmunity
-Th cell driven, releases inflammatory cytokines. Rheumatoid arthritis, MS
-Cytotoxic T Cell driven - Type 1 diabetes.
Type 1 diabetes
Cytotoxic T cell driven autoimmunity of islet beta cells.
What are the T helper cells and cytokines involved in Th Cell driven autoimmunity?
Th1 and Th17, and IL17.
What are the T cells and cytokines involved in regulating immunity?
Treg and Th2, with IL10.
Rheumatoid Arthritis key features
-Symptoms >6 weeks
-Synovitis; swollen joints (not distal phalangeal)
-Symmetrical and polyarticular
-High serum rheumatoid factor
-may be mild or severe and may progesss.
RA vs OA
-responds to NSAIDs
-not distal joint
-stiffness last for hours
-improves with use
-loss of function
-Redness and warmth
-vasculitis (blod blisters)
-Not responsive to NSAIDs
-Stiffness lasts mintutes
-worsens with use
RA therapeutic approach
-COX2 NSAIDs for symptomatic relief.
-intra articular steroids for flareups
-Disease Modifying Anti-Rheumetic Drugs
-Anti TNF alfa
-B cell inhibitors
-IL1 receptor agonist
DMARDs, triple therapy
Disease Modifying Anti-Rheumetic Drugs
-Tripple Rx works better than any single therapy.
Require frequent monitoring.
Best single DMARD. Low doses. Good risk/benefit ratio. Used in Psoriasis, RA and post transplant. Give folic acid supplementation.
Different mechanism than in cancer: Inhibition of enzymes involved in purine metabolism, leading to accumulation of adenosine; inhibition of T cell activation and suppression of intercellular adhesion molecule expression by T cells; selective down-regulation of B cells; and the inhibition of the binding of IL1 to its cell surface receptor.
Adverse reactions include: pulmonary damage, myelosupression, GI problems (nausea, stomach upset, and loose stools), Stomatitis and soreness of mouth, infection, alopecia.
Multiple sclerosis (MS) is a demyelinating disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged. This damage disrupts the ability of parts of the nervous system to communicate, resulting in a range of signs and symptoms, including physical, mental, and sometimes psychiatric problems.
Fingolimod is an immunomodulating drug, mostly used for treating multiple sclerosis (MS). Fingolimod is a sphingosine-1-phosphate receptor modulator, which sequesters lymphocytes in lymph nodes, preventing them from contributing to an autoimmune reaction.
Natalizumab is a monoclonal antibody against the cell adhesion molecule α4-integrin. Natalizumab is used in the treatment of multiple sclerosis and Crohn's disease. Natalizumab appears to reduce the transmission of immune cells into the central nervous system by interfering with the α4β1-integrin receptor molecules on the surfaces of cells.
IgE plays a role in parasitic worm diseases via the Th2 immune response. Eosinophils have Fc receptors for IgE and binding of eosinophils to IgE-coated helminths results in killing of the parasite.